IL160295A0 - Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases - Google Patents

Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Info

Publication number
IL160295A0
IL160295A0 IL16029502A IL16029502A IL160295A0 IL 160295 A0 IL160295 A0 IL 160295A0 IL 16029502 A IL16029502 A IL 16029502A IL 16029502 A IL16029502 A IL 16029502A IL 160295 A0 IL160295 A0 IL 160295A0
Authority
IL
Israel
Prior art keywords
inflammations
cathepsin
pyrimidines
cyano
diseases
Prior art date
Application number
IL16029502A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121024A external-priority patent/GB0121024D0/en
Priority claimed from GBGB0121026.9A external-priority patent/GB0121026D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL160295A0 publication Critical patent/IL160295A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL16029502A 2001-08-30 2002-08-29 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases IL160295A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121024A GB0121024D0 (en) 2001-08-30 2001-08-30 Organic compounds
GBGB0121026.9A GB0121026D0 (en) 2001-08-30 2001-08-30 Organic compounds
PCT/EP2002/009661 WO2003020278A1 (fr) 2001-08-30 2002-08-29 Inhibiteurs de cysteine protease ayant une structure de 2-cyano-4-amino-pyrimidine et une activite d'inhibition de cathepsine k, pour traiter les inflammations et autres troubles

Publications (1)

Publication Number Publication Date
IL160295A0 true IL160295A0 (en) 2004-07-25

Family

ID=26246490

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16029502A IL160295A0 (en) 2001-08-30 2002-08-29 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases

Country Status (22)

Country Link
US (2) US7112589B2 (fr)
EP (1) EP1423121B1 (fr)
JP (1) JP4131701B2 (fr)
KR (1) KR100629834B1 (fr)
CN (1) CN1549717B (fr)
AR (1) AR036375A1 (fr)
AT (1) ATE345136T1 (fr)
AU (1) AU2002333758B2 (fr)
BR (1) BR0212141A (fr)
CA (1) CA2456127C (fr)
CO (1) CO5560576A2 (fr)
DE (1) DE60216122T2 (fr)
ES (1) ES2275946T3 (fr)
HU (1) HUP0401431A3 (fr)
IL (1) IL160295A0 (fr)
MX (1) MXPA04001930A (fr)
NZ (1) NZ531287A (fr)
PE (1) PE20030772A1 (fr)
PL (1) PL208280B1 (fr)
PT (1) PT1423121E (fr)
RU (1) RU2326119C2 (fr)
WO (1) WO2003020278A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0220187D0 (en) * 2002-08-30 2002-10-09 Novartis Ag Organic compounds
BRPI0412769A (pt) * 2003-07-21 2006-09-26 Novartis Ag combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor
WO2005011703A1 (fr) * 2003-08-04 2005-02-10 Akzo Nobel N.V. Derives 2-cyano-1,3,5-triazine-4,6-diamines
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
US20070135448A1 (en) * 2003-11-19 2007-06-14 Martin Missbach Use of cathepsin k inhibitors for treating of severe bone loss diseases
WO2005103012A1 (fr) * 2004-04-21 2005-11-03 Ono Pharmaceutical Co., Ltd. Composés nitriles hétérocycliques substitués par un hydrazino et utilisation de ceux-ci
TW200614993A (en) 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
PE20060718A1 (es) * 2004-09-07 2006-10-04 Glaxo Group Ltd Compuestos 2-ciano pirimidinas sustitituidas como inhibidores de cisteina proteasas
WO2006040300A1 (fr) * 2004-10-12 2006-04-20 N.V. Organon Derives de 4-cycloalkyl-pyrimidine-2-carbonitrile
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
GB0514684D0 (en) * 2005-07-18 2005-08-24 Novartis Ag Organic compounds
CA2617725C (fr) * 2005-08-05 2012-04-03 Hybrigenics Sa Nouveaux inhibiteurs des proteases a cysteine et leurs applications therapeutiques
TW200804351A (en) * 2005-09-02 2008-01-16 Glaxo Group Ltd Novel cysteine protease inhibitors
US7326715B2 (en) 2005-09-23 2008-02-05 N.V. Organon 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
TW200745055A (en) * 2005-09-23 2007-12-16 Organon Nv 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives
US7687515B2 (en) 2006-01-17 2010-03-30 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
WO2007137149A2 (fr) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Utilisation d'antagonistes de la cathepsine k dans la production osseuse
CN101479269A (zh) * 2006-06-23 2009-07-08 阿斯利康(瑞典)有限公司 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途
EP1947091A1 (fr) * 2007-01-16 2008-07-23 Glaxo Group Limited Dérivés de pyrimidyl nitrile comme inhibiteurs de la cystéine protéase
US7932251B2 (en) 2007-07-16 2011-04-26 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
US8354446B2 (en) 2007-12-21 2013-01-15 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (SARMs) and uses thereof
EP2240491B1 (fr) 2008-01-09 2015-07-15 Amura Therapeutics Limited DÉRIVÉS DE TÉTRAHYDROFURO(2,3-b)PYRROL-3-ONE COMME INHIBITEURS DE CYSTÉINE PROTÉINASES
US8026236B2 (en) 2009-01-16 2011-09-27 N.V. Organon 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
TW201035094A (en) 2009-01-16 2010-10-01 Organon Nv 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
EP2316820A1 (fr) * 2009-10-28 2011-05-04 Dompe S.p.A. Dérivés de 2-aryl-propionamide utiles en tant qu'antagonistes de récepteur de bradykinine et compositions pharmaceutiques les contenant
EP2523954B1 (fr) 2010-01-15 2014-04-16 Merck Sharp & Dohme B.V. Dérivés de 1h-[1,2,3]triazolo[4,5-c]pyridine-4- carbonitrile comme inhibiteurs de cathepsine s
AU2011311452B2 (en) 2010-10-06 2016-09-01 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of breast cancer metastasis
US8524710B2 (en) * 2010-11-05 2013-09-03 Hoffmann-La Roche Inc. Pyrrolidine derivatives
EP2650682A1 (fr) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants
AU2013273242B2 (en) 2012-06-06 2019-04-11 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140105918A1 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
JP6577873B2 (ja) 2013-03-15 2019-09-18 フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ（イエレベ、バルセロナ）Ｆｕｎｄａｃｉｏ Ｉｎｓｔｉｔｕｔ Ｄｅ Ｒｅｃｅｒｃａ Ｂｉｏｍｅｄｉｃａ （Ｉｒｂ Ｂａｒｃｅｌｏｎａ） がんの転移の予後診断および処置のための方法
WO2014184679A2 (fr) 2013-03-15 2014-11-20 Inbiomotion S.L. Procédé de pronostic et de traitement de la métastase d'un carcinome des cellules rénales
TR201907389T4 (tr) 2013-10-09 2019-06-21 Fundacio Inst De Recerca Biomedica Irb Barcelona Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
WO2015108988A2 (fr) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Méthodes et compositions pour moduler les taux d'hormone
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
WO2017203468A1 (fr) 2016-05-25 2017-11-30 Inbiomotion S.L. Traitement thérapeutique du cancer du sein sur la base de l'état c-maf
SG11201906871XA (en) * 2017-01-27 2019-08-27 Genfit Rorgamma modulators and uses thereof
CN108586356B (zh) * 2017-03-16 2021-02-19 杭州科巢生物科技有限公司 瑞博西尼新中间体及其制备瑞博西尼的合成方法
EP3713581A1 (fr) 2017-11-22 2020-09-30 Inbiomotion S.L. Traitement thérapeutique du cancer du sein basé sur le c-maf
CN109467536B (zh) * 2018-12-23 2020-06-05 沧州普瑞东方科技有限公司 2-氯/羟基嘧啶-5-羧酸的合成方法
US20220193048A1 (en) 2019-04-05 2022-06-23 Universite De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270922A (fr) 1960-11-02
NL295648A (fr) * 1962-07-26
BR6915234D0 (pt) 1969-05-22 1973-06-07 American Cyanamid Co Novos derivados de melamina e processo para sua preparaca
CH627919A5 (de) * 1977-04-14 1982-02-15 Ciba Geigy Ag Herbizide mittel.
CA2230894A1 (fr) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Carboxamides de pyrimidine et composes associes, et methodes de traitement d'etats inflammatoires
EP0880501A1 (fr) 1996-02-02 1998-12-02 Zeneca Limited Composes heterocycliques utiles en tant qu'agents pharmaceutiques
DE19817459A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
JP2003529546A (ja) * 1999-09-13 2003-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆的インヒビターとして有益な新規スピロ複素環化合物
CN102584799A (zh) * 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
KR100711042B1 (ko) 2000-04-28 2007-04-24 다나베 세이야꾸 가부시키가이샤 환상 화합물
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
SE0201976D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20040249153A1 (en) 2004-12-09
CA2456127C (fr) 2009-10-20
PL367821A1 (en) 2005-03-07
AR036375A1 (es) 2004-09-01
CN1549717A (zh) 2004-11-24
US7112589B2 (en) 2006-09-26
AU2002333758B2 (en) 2006-01-19
EP1423121A1 (fr) 2004-06-02
HUP0401431A2 (hu) 2004-10-28
RU2326119C2 (ru) 2008-06-10
MXPA04001930A (es) 2004-06-15
CN1549717B (zh) 2011-08-17
JP4131701B2 (ja) 2008-08-13
BR0212141A (pt) 2004-08-24
JP2005505550A (ja) 2005-02-24
DE60216122T2 (de) 2007-09-06
RU2004109812A (ru) 2005-10-20
NZ531287A (en) 2005-12-23
CO5560576A2 (es) 2005-09-30
HUP0401431A3 (en) 2004-11-29
CA2456127A1 (fr) 2003-03-13
ATE345136T1 (de) 2006-12-15
WO2003020278A1 (fr) 2003-03-13
KR100629834B1 (ko) 2006-09-29
US20060074092A1 (en) 2006-04-06
PT1423121E (pt) 2007-02-28
PL208280B1 (pl) 2011-04-29
ES2275946T3 (es) 2007-06-16
PE20030772A1 (es) 2003-10-02
DE60216122D1 (de) 2006-12-28
KR20040029101A (ko) 2004-04-03
EP1423121B1 (fr) 2006-11-15

Similar Documents

Publication Publication Date Title
IL160295A0 (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidines structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
PL343373A1 (en) Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
HK1163061A1 (en) Peptidomimetic protease inhibitors and intermediates for their preparation as treatment for hcv infection
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
PL375487A1 (en) Topical treatment of skin diseases
AU2003267532A1 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF Alpha-SYNUCLEIN-RELATED DISEASES
AU2002241661A1 (en) Multifunctional protease inhibitors and their use in treatment of disease
AU2002346594A1 (en) Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
AU2003239184A8 (en) Treatment and inhibition of ocular infections and wounds by cap37 and cap37 peptides
AU2003297363A1 (en) Use of cathepsin k inhibitors for the treatment of glaucoma
AU9545701A (en) Use of carp inhibitors for the treatment of heart diseases
IL156776A0 (en) Inhibitors of cruzipain and other cysteine proteases
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2001231137A1 (en) Treatment of neuropsychiatric disease with protease and neuraminidase inhibitors
NO20040858L (no) Cystein-proteinase-inhibitorer med 2-cyano-4-aminopyrimidinstruktur og kathepsin K-inhibitoraktivitet for behandling av inflammasjoner og andre sykdommer
AU2003250830A8 (en) Regulation of human subtilase-like serine protease
MXPA01010541A (es) Cisteina proteasa e hinibidores para la prevencion y el tratamiento de la neurocisticercosis.
AU2002338524A1 (en) Inhibitors of human rhinovirus 2a cysteine protease
EP1433848A4 (fr) Nouvelle proteine mt0039 inhibitrice de serine protease
AU2003297570A1 (en) Treatment of skin diseases
TJ11Y3 (en) The ointment "Origanolum" for treatment of wounds and calds
AU2002365654A1 (en) Treatment of diseases via the skin
WO2002055064A3 (fr) Traitement des mucopolysaccharidoses